Category: T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.

Accuracy of the Zika IgM Antibody Capture Enzyme-Linked Immunosorbent Assay
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients
Economic aspects of established antibodies and recently available therapies
Impact of Immune Priming, Vaccination and Infection on Influenza A
Systemic phenotype associated to major Sjögren’s syndrome in 279 sufferers
Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin
T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.
T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.

Glioblastoma multiforme (GBM) is the most typical major malignant braintumor in adults with a dismal prognosis. We beforehand reported that vaccination with heat shock protein peptide complex-96 (HSPPC-96) improves survival in sufferers with newly diagnosed GBM (NCT02122822). Especially for sufferers with a sturdy antitumor immune response after vaccination, a sturdy survival profit will be achieved. Here, we performed […]

Back to top